CVR 29150397Limited partnership (K/S)Uoplyst (999999)København KFounded 25 Oct 2005
CVR lists no current officers for this company.
CVR holds no employment figures for this company.
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about NORDIC BIOTECH VENTURE FUND II K/S, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexGross profit
-371.2K
EUR, annual report 2013
Result
-371.3K
EUR, annual report 2013
Equity
350.2K
EUR, annual report 2013
NORDIC BIOTECH GENERAL PARTNER II ApSCVR 29148805, until 20 Aug 2014
No current partner is registered.
Liable for the company's debts without limit (fuldt ansvarlige deltagere).
CVR 2914880525 Oct 2005 to 20 Aug 2014
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
The company's own figures, in EUR, from the annual reports filed in XBRL.
2013, EUR: Gross profit -371.2K, Result for the year -371.3K
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2013, EUR: Total assets 371.5K, Equity 350.2K
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| EUR thousands | 2009 | 2010 | 2011 | 2012 | 2013 |
|---|---|---|---|---|---|
| Gross profit | Not reported | Not reported | Not reported | -10,910 | -371 |
| Operating profit | Not reported | Not reported | Not reported | Not reported | -371 |
| Result for the year | Not reported | Not reported | Not reported | -10,912 | -371 |
| Equity | Not reported | Not reported | Not reported | 721 | 350 |
| Total assets | Not reported | Not reported | Not reported | 741 | 372 |
| Credit metrics (Dandex calculations) | |||||
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for NORDIC BIOTECH VENTURE FUND II K/S:
Have Pro? Sign in.
Source: CVR, read 19 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 19 Nov 2026.
6 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Retsform:
Kommanditselskab.
Virksomheden er slettet af registeret, jf. lov om visse erhvervsdrivende virksomheder § 12.
Retsform:
Kommanditselskab.
Vedtægter ændret:
13.02.2013.
Retsform:
Kommanditselskab.
Ny adresse:
c/o NB Capital ApS, Østergade 24A, 1. tv., 1100 København K.
Retsform:
Kommanditselskab.
Vedtægter ændret:
12.07.2006.
Retsform:
Kommanditselskab.
Seneste vedtægtsdato:
25.10.2005.
Komplementar: CVR-NR. 29148805 NORDIC BIOTECH GENERAL PARTNER II ApS, Østergade 5, 3., 1100 København K, den 25.10.2005.
Daglig ledelse: CVR-NR. 29148805 NORDIC BIOTECH GENERAL PARTNER II ApS, Østergade 5, 3., 1100 København K, den 25.10.2005.
Selskabet tegnes af komplementaren.
Revision:
CVR-NR. 73317428 ERNST & YOUNG STATSAUTORISERET REVISIONSAKTIESELSKAB, Tagensvej 86, 2200 København N, den 25.10.2005.
Første regnskabsår:
25.10.2005 - 31.12.2006.
Regnskabsår:
01.01 - 31.12.
P-number 1011786789Østergade 24, 1100 København K